Versartis Grabs $21M

Xconomy San Francisco — 

Mountain View, CA-based Versartis, the developer of protein drugs for endocrine disorders, said today it has raised $21 million in its Series B financing. The deal was led by New Leaf Venture Partners and Advent Venture Partners’ Advent Life Sciences fund, and included existing investors Index Ventures and Amunix. The company plans to use the money to run clinical trials of a once-monthly injectible form of human growth hormone for adults and children with deficiencies.